Update on the use of ciclosporin in immune-mediated dermatoses

British Journal of Dermatology

Volumn 155, Issue SUPPL. 2, 2006, Pages 1-16

  Griffiths, C E M ^a,j   Katsambas, A ^b   Dijkmans, B A C ^c   Finlay, A Y ^d,j   Ho, V C ^e   Johnston, A ^f,j   Luger, T A ^g   Mrowietz, U ^h   Thestrup Pedersen, K ^i,j  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF ATHENS   (Greece)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g UNIVERSITY OF MÜNSTER   (Germany)

^h UNIVERSITY OF KIEL   (Germany)

ⁱ AARHUS UNIVERSITY   (Denmark)

^j Novartis ^*  (Switzerland)

more..

Author keywords

Calcineurin inhibitor; Ciclosporin; Dermatoses; Efficacy; Immune mediated; Safety

Indexed keywords

ANTIHISTAMINIC AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETRETIN; IMMUNOMODULATING AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PSORALEN; SALAZOSULFAPYRIDINE; STEROID;

ARTHRALGIA; ATOPIC DERMATITIS; AUTOIMMUNE SKIN DISEASE; BLOOD PRESSURE MONITORING; BULLOUS DERMATITIS; CHRONIC URTICARIA; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EPIDERMOLYSIS BULLOSA ACQUISITA; HAND ECZEMA; HEADACHE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FUNCTION; LICHEN PLANUS; LONG TERM CARE; MYALGIA; NAUSEA; NEPHROTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; PEMPHIGUS VULGARIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; PUVA; PYODERMA GANGRENOSUM; QUALITY OF LIFE; REVIEW; SCLERODERMA; SHORT COURSE THERAPY; SKIN ALLERGY; SKIN CANCER; SKIN DISEASE; SKIN INFLAMMATION; TREATMENT OUTCOME;

ARTHRITIS, PSORIATIC; CYCLOSPORINE; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; PSORIASIS; QUALITY OF LIFE; SKIN DISEASES; SKIN DISEASES, PAPULOSQUAMOUS;

EID: 33744960664     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07343.x     Document Type: Review

References (93)

1. Kaminska B Gaweda-Walerych Z Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants - facts and hypotheses. J Cell Mol Med 2004 8: 45 58.
2. Stein CM Murray JJ Wood AJJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem 1999 49: 1477 84.
3. Mrowietz U Ruzicka T. Cyclosporin A for psoriasis. Dermatologic Ther 1999 11: 60 6.
4. Bowcock AM Krueger JG. Getting under the skin: immunogenetics of psoriasis. Nat Rev Immunol 2005 5: 699 711.
5. Griffiths CEM Clark CM Chalmers RJG et al. A systematic review of treatments for severe psoriasis. Health Tech Assess 2000 4: 40.
6. Fry L. Psoriasis. Br J Dermatol 1988 119: 445 61.
7. Bang K Lund M Mogensen SC Threstrup-Pedersen K. In vitro culture of skin-homing T lymphocytes from inflammatory skin diseases. Exp Dermatol 2005 14: 391 7.
8. Finlay AY Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995 132: 236 44.
9. Finlay AY. Measures of the effect of adult severe atopic eczema on quality of life. J Eur Acad Dermatol Venereol 1996 7: 149 54.
10. Kiebert G Sorensen SV Revicki D et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002 41: 151 8.
11. Paller AS McAllister RO Doyle JJ Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr 2002 41: 323 32.
12. Rapp SR Feldman SR Exum MI et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41: 401 7.
13. Stern RS Nijsten T Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004 9: 136 9.
14. Holm EA Esmann S Jemec GB. Does visible atopic dermatitis affect quality of life more in women than in men? Gend Med 2004 1: 125 30.
15. Renzi C Picardi A Abeni D et al. Association of dissatisfaction with care and psychiatric morbidity with poor treatment compliance. Arch Dermatol 2002 138: 337 42.
16. David SE Ahmed Z Salek MS Finlay AY. Does enough quality of life related discussion occur during dermatology outpatient consultations? Br J Dermatol 2005 153: 997 1000.
17. Lewis V Finlay AY. Ten years' experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004 9: 169 80.
18. Finlay AY Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 19: 210 6.
19. Hongbo Y Thomas CL Harrison MA et al. Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean? J Invest Dermatol 2005 125: 659 64.
20. Melilli L Shikiar R Thompson C. Clinical responses to treatment and changes in the dermatology life quality index (DLQI) in moderate to severe plaque psoriasis patients treated with adalimumab. J Eur Acad Dermatol Venereol 2005 19 Suppl. 2 FC 13.1 (CD-ROM).
21. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005 152: 861 7.
22. Smith CH Anstey AV Barker JNWN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153: 486 97.
23. Ho VCY Griffiths CEM Albrecht G et al. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomised study. Br J Dermatol 1999 141: 283 91.
24. Touw CR Hakkaart-Van Roijen L Paul C et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001 144: 967 72.
25. Vanaclocha F Puig L Daudén E et al. Effectiveness of cyclosporine in patients with psoriasis. Poster presented at 9th International Psoriasis Symposium, New York, 17-22 June 2003.
26. Puig L Vanaclocha F Daudén E et al. Quality of life in psoriatic patients treated with cyclosporine. Poster presented at 9th International Psoriasis Symposium, New York, 17-22 June 2003.
27. Salek MS Finlay AY Luscombe DK et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized double blind placebo-controlled trial. Br J Dermatol 1993 129: 422 30.
28. Harper JI Ahmed IA Barclay G et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. Br J Dermatol 2000 142: 52 8.
29. Czech W Bräutigam M Weidinger G Schöpf E. A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves quality of life. J Am Acad Dermatol 2000 42: 653 9.
30. Richards HL Fortune DG O'Sullivan TM et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999 41: 581 3.
31. Ho VC. The use of ciclosporin in psoriasis: a clinical review. Br J Dermatol 2004 150 Suppl. 67 S1 10.
32. Griffiths CEM Dubertret L Ellis CN et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004 150 Suppl. 67 S11 23.
33. Müller W Herrmann B. Ciclosporin A for psoriasis. N Engl J Med 1979 301: 555.
34. Ellis CN Fradin MS Messana JM et al. Cyclosporine for plaque-type psoriasis: results of a multi-dose, double-blind trial. N Engl J Med 1991 324: 277 84.
35. Finzi AF, ed. Cyclosporin in severe psoriasis: The Italian experience. Dermatology 1993 187 Suppl. 1 J Henderson CA Munro CS et al. Treatment of psoriasis with intermittent short-course cyclosporin (Neoral®). A multicentre study. Br J Dermatol 1997 136: 527 30.
36. Ho VCY Griffiths CEM Berth-Jones J et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001 44: 643 51.
37. Faerber L Braeutigam M Weidinger G et al. Cyclosporine in severe psoriasis: results of a meta-analysis. Am J Clin Dermatol 2001 2: 41 7.
38. Shupack J Abel E Bauer E et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997 36: 423 32.
39. Mrowietz U Färber L Henneicke-von Zepelin HH et al. Long-term maintenance therapy with cyclosporine and post-treatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study. J Am Acad Dermatol 1995 33: 470 5.
40. Christophers E Mrowietz U Henneicke HH et al. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. J Am Acad Dermatol 1992 26: 86 90.
41. Powles AV Baker BS Valdimarsson H et al. Four years of experience with cyclosporin A for psoriasis. Br J Dermatol Supplement 1990 36: 13 9.
42. Ellis CN Fradin MS Hamilton TA et al. Duration of remission during maintenance ciclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol 1995 131: 791 5.
43. Koo J for the OLP302 Study Group. A randomised, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. Br J Dermatol 1998 139: 88 95.
44. Markham T Watson A Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol 2002 27: 111 4.
45. Garcia-Bustinduy M Escoda M Guimera FJ et al. Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series. J Eur Acad Dermatol Venereol 2004 18: 169 72.
46. Fradin MS Ellis CN Voorhees JJ et al. Rapid response of von Zumbusch psoriasis to ciclosporine. J Am Acad Dermatol 1990 23: 925 6.
47. Ellis CN Krueger GG for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 345: 248 55.
48. Mrowietz U. Advances in systemic therapy for psoriasis. Clin Exp Dermatol 2001 26: 362 7.
49. Mrowietz U. Treatment targeted to cell surface epitopes. Clin Exp Dermatol 2002 27: 591 6.
50. Davison SC Morris-Jones R Powles AV Fry L. Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br J Dermatol 2000 143: 405 7.
51. Salvarani C Macchioni P Olivieri I et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001 28: 2274 82.
52. Sarzi-Puttini P Cazzola M Panni B et al. Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. Rheumatol Int 2002 21: 234 8.
53. Fraser AD van-Kuijk AWR Westhovens R et al. A randomised, double blind, placebo controlled multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005 64: 859 64.
54. Granlund H Errko P Remitz A et al. Comparison of cyclosporin and UVAB phototherapy for intermittent one-year treatment of atopic dermatitis. Acta Derm Venereol 2001 81: 22 7.
55. Schiffner R Schiffner-Rohe J Landthaler M Stolz W. Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids. Pharmacoeconomics 2003 21: 159 79.
56. Ellison JA Patel L Ray DW et al. Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis. Paediatrics 2000 105: 794 9.
57. Ellis C Luger T, on behalf of the ICCAD II Faculty. International consensus conference in atopic dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003 148 Suppl. 63 3 10.
58. Olesen AB Bang K Juul S Thestrup-Pedersen K. Stable incidence of atopic dermatitis among children in Denmark during the 1990s. Acta Derm Venereol 2005 85: 244 7.
59. Van Joost T Stolz E Heule F. Efficacy of low-dose cyclosporin in severe atopic skin disease. Arch Dermatol 1987 123: 166 7.
60. Sowden J Berth-Jones J Ross J et al. Double-blind controlled crossover study of cyclosporin in adults with severe atopic dermatitis. Lancet 1991 338: 137 40.
61. Von Rüden U Bunikowski R Bräutigam M Staab D. Cyclosporin A treatment of children with severe atopic dermatitis improves quality of life of their mothers. Dermatol Psychosom 2002 3: 14 8.
62. Bolognia JL Jorizzo JL Rapini RP. Dermatology (on-Line). Amsterdam: Elsevier 2003, Available at URL: http://www.dermtext.com
63. Vidal D Puig L Gilaberte M Alomar A. Review of 26 cases of classical pyoderma gangrenosum: clinical and therapuetic features. J Dermatol Treat 2004 15: 146 52.
64. Friedman S Marion JF Scherl E et al. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis 2001 7: 1 7.
65. Reichrath J Bens G Bonowitz A Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol 2005 53: 273 83.
66. Erkko P Granlund H Remitz A et al. Double-blind placebo-controlled study of long-term low-dose cyclosporin in the treatment of palmoplantar pustulosis. Br J Dermatol 1998 139: 997 1004.
67. Harman KE Albert S Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003 159: 926 37.
68. Lapidoth M David M Ben-Amitai D et al. The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol 1994 30: 752 7.
69. Katta R. Lichen planus. Am Fam Physician 2000 61: 3319 28.
70. Ho VC Gupta AK Ellis CN et al. Treatment of severe lichen planus with ciclosporine. J Am Acad Dermatol 1990 22: 64 8.
71. Thorne JE Jabs DA Nikolskaia OV et al. Lichen planus and cicatrizing conjunctivitis: characterization of five cases. Am J Ophthalmol 2003 136: 239 43.
72. Eisen DE Ellis CN Duell EA et al. Effect of topical ciclosporine rinse on oral lichen planus: a double-blind analysis. N Engl J Med 1990 323: 290 4.
73. Demitsu T Sato T Inoue T Okada O Kubota T. Corticosteroid-resistant erosive oral lichen planus successfully treated with topical cyclosporine therapy. Int J Dermatol 2000 39: 79 80.
74. Pacj M Silva R. Treatment of plantar erosive lichen planus with topical cyclosporin. J Eur Acad Dermatol Venereol 2001 15: 79 80.
75. Mirmirani P Willey A Price VH. Short course of oral cyclosporine in lichen planopilaris. J Am Acad Dermatol 2003 49: 667 71.
76. Fradin MS Ellis CN Goldfarb MT et al. Oral ciclosporine for severe chronic idiopathic urticaria and angioedema. J Am Acad Dermatol 1991 25: 1065 7.
77. Di Gioacchino M Di Stefano F Cavallucci E et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc 2003 24: 285 90.
78. Grattan CEH O'Donnell BF Francio DM et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000 143: 365 72.
79. Engineer L Ahmed AR. Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol 2001 44: 818 28.
80. Morton SJ Powell RJ. Cyclosporin and tacrolimus: their use in a routine clinical setting for scleroderma. Rheumatology 2000 39: 865 9.
81. Dauden E Garcia-Diez A. Severe resistant subacute prurigo successfully controlled by long-term cyclosporin. J Dermatol Treat 2003 14: 48 50.
82. Serkova N Christians U. Transplantation: toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr Opin Invest Drugs 2003 4: 1287 96.
83. Mihatsch MJ Wolff K. A consensus report: cyclosporin A therapy for psoriasis. Br J Dermatol 1990 122 Suppl. 26 1 3.
84. Young EW Ellis CN Messana JM et al. A prospective study of renal structure and function in psoriasis patients treated with ciclosporin. Kidney Int 1994 46: 1216 22.
85. Feutren G Mihatsch MJ. Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporin in Autoimmune Diseases. N Engl J Med 1992 326: 1654 60.
86. Lowe NJ Wieder JM Rosenbach A et al. Long-term low-dose cyclosporine therapy for severe psoriasis. Effects on renal function and structure. J Am Acad Dermatol 1996 35: 710 9.
87. Paul CF Ho VC McGeown C et al. Risk of malignancies in psoriasis treated with cyclosporine: a 5-yr cohort study. J Invest Dermatol 2003 120: 211 6.
88. Marcil I Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001 358: 1042 5.
89. Taber DJ Baillie GM Ashcraft EA et al. Does bioequivalence between modified cyclosporine formulations translate into equal outcomes? Transplantation 2005 80: 1633 5.
90. Johnston A Keown PA Holt DW. Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine. Ther Drug Monit 1997 19: 375 81.
91. Johnston A Holt DW. Bioequivalence criteria for cyclosporine. Transplant Proc 1999 31: 1649 53.
92. Pollard S Nashan B Johnston A et al. A pharmacokinetic and clinical review of the potential clinical impact of using different formulations of cyclosporin A. Clin Ther 2003 25: 1654 69.
93. British National Formulary. Corticosteroids and Other Immunosuppressants - Ciclosporin, Vol. 50, Section 8.2.2. September 2005 (also available at URL: http://www.bnf.org).